For example, previous work has shown that pharmacological inhibition of FOXO1 can ameliorate cardiac defects associated with type 2 diabetes by suppressing PDK4 and thereby increasing PDH activity50. This evidence concerns the gene FOXO1 and type 2 diabetes mellitus.